Hunan Er-Kang Pharmaceutical Co., Ltd signed an equity transfer agreement to acquire Wuzhiwei Er-Kang Biochemical Pharmaceutical Co., Ltd. from Nanyu Xingkang Pharmaceutical Co., Ltd. for CNY 58 million.
May 07, 2020
Share
Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) signed an equity transfer agreement to acquire Wuzhiwei Er-Kang Biochemical Pharmaceutical Co., Ltd. from Nanyu Xingkang Pharmaceutical Co., Ltd. for CNY 58 million on May 8, 2020. The consideration will be completed within 3 days since signing of the respective agreement. For the year ended December 31, 2019, Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) reported total assets of CNY 74.5 million, net assets of CNY 60.1 million, operating revenue of CNY 0 and net loss of CNY 2.8 million. The transaction was approved by the 7th meeting of the 4th directorate of Hunan Er-Kang Pharmaceutical Co., Ltd.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and sales of pharmaceutical excipients, finished drugs and bulk drugs. The Companyâs pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The Company distributes its products in domestic market and to overseas markets.
Hunan Er-Kang Pharmaceutical Co., Ltd signed an equity transfer agreement to acquire Wuzhiwei Er-Kang Biochemical Pharmaceutical Co., Ltd. from Nanyu Xingkang Pharmaceutical Co., Ltd. for CNY 58 million.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD 
